(Q37493951)

20 August 2017

1 reference

title

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network (English)

1 reference

20 August 2017

1 reference

E Terpos

1

1 reference

20 August 2017

O Sezer

2

1 reference

20 August 2017

P I Croucher

3

1 reference

20 August 2017

R García-Sanz

4

1 reference

20 August 2017

M Boccadoro

5

1 reference

20 August 2017

J San Miguel

6

1 reference

20 August 2017

J Ashcroft

7

1 reference

20 August 2017

J Bladé

8

1 reference

20 August 2017

M Cavo

9

1 reference

20 August 2017

M Delforge

10

1 reference

20 August 2017

M-A Dimopoulos

11

1 reference

20 August 2017

T Facon

12

1 reference

20 August 2017

M Macro

13

1 reference

20 August 2017

A Waage

14

1 reference

20 August 2017

P Sonneveld

15

1 reference

20 August 2017

European Myeloma Network

16

1 reference

20 August 2017

publication date

22 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

20

1 reference

20 August 2017

issue

8

1 reference

20 August 2017

page(s)

1303-1317

1 reference

Diagnosis and management of multiple myeloma

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Recent major improvement in long-term survival of younger patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Review of 1027 patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

The use of bisphosphonates in elderly cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Myeloma bone disease: pathophysiology and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Zoledronic acid: a review of its use in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Proteasome inhibition as a new therapeutic principle in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

New insights into the pathophysiology and management of bone disease in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

RANK ligand and osteoprotegerin in myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Multiple myeloma biology: lessons from the 5TMM models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Managing metastatic bone pain: the role of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Vertebroplasty in multiple myeloma: outcomes in a large patient series

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Bone complications in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

A systematic review of persistence and compliance with bisphosphonates for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Bisphosphonate infusions: patient preference, safety and clinic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Clodronate in the prevention and treatment of skeletal metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Perspective study on pamidronate in stage I multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Gammadelta T cells for immune therapy of patients with lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Anti-tumor activity of pamidronate in human multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Esophagitis associated with the use of alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Complementary and alternative therapies for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Management of the adverse effects associated with intravenous bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

An unusual coma after therapy for bone pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Severe hypocalcaemia after being given intravenous bisphosphonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Toxic acute tubular necrosis following treatment with zoledronate (Zometa).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Renal Failure with the Use of Zoledronic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Renal Safety and Pharmacokinetics of Ibandronate in Multiple Myeloma Patients With or Without Impaired Renal Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Nephrotic syndrome after treatment with pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Osteonecrosis of the jaw and bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

The role of markers of bone remodeling in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Bone markers in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Bortezomib inhibits human osteoclastogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

PET/CT and MR imaging in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Value of FDG PET in the assessment of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Role of MRI for the diagnosis and prognosis of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN796

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDN796

1 reference

20 August 2017

1 reference